{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:33:05Z","timestamp":1768926785812,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T00:00:00Z","timestamp":1481328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s10384-016-0490-9","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T12:45:01Z","timestamp":1481373901000},"page":"169-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diltiazem co treatment with cyclosporine for induction of disease remission in sight-threatening non-infectious intraocular inflammation"],"prefix":"10.1007","volume":"61","author":[{"given":"Usama","family":"Shalaby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,10]]},"reference":[{"key":"490_CR1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hlca.19760590412","volume":"59","author":"A Ruegger","year":"1976","unstructured":"Ruegger A, Kuhn M, Lichti H, Loosli HR, Huguenin R, Quiquerez C, et al. Cyclosporin-A, a peptide metabolite from Trichoderma polysporum Rifai, with a remarkable immunosuppressive activity. Helv Chim Acta. 1976;59:1075\u201392.","journal-title":"Helv Chim Acta"},{"key":"490_CR2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1001\/archopht.1982.01030040124022","volume":"100","author":"RB Nussenblatt","year":"1982","unstructured":"Nussenblatt RB, Rodrigues MM, Salinas-Carmona MC, Gery I, Cevario S, Wacker W. Modulation of experimental autommune uveitis with cyclosporine-A. Arch Ophthalmol. 1982;100:1146\u20139.","journal-title":"Arch Ophthalmol"},{"key":"490_CR3","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0140-6736(79)92082-8","volume":"29","author":"DJ Coster","year":"1979","unstructured":"Coster DJ, Shepherd WF, Fook TC, Rice NS, Jones BR. Prolonged survival of corneal allografts in rabbits treated with cyclosporin A. Lancet. 1979;29:688\u20139.","journal-title":"Lancet"},{"key":"490_CR4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(83)90230-1","volume":"2","author":"RB Nussenblatt","year":"1983","unstructured":"Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I. Treatment of intraocular inflammatory disease with cylosporin A. Lancet. 1983;2:235\u20138.","journal-title":"Lancet"},{"key":"490_CR5","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/clinchem\/35.7.1299","volume":"35","author":"LM Shaw","year":"1989","unstructured":"Shaw LM. Advances in cyclosporine pharmacology, measurement and therapeutic monitoring. Clin Chem. 1989;35:1299\u2013308.","journal-title":"Clin Chem"},{"key":"490_CR6","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","volume":"338","author":"JC Kolars","year":"1991","unstructured":"Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet. 1991;338:1488\u201390.","journal-title":"Lancet"},{"key":"490_CR7","first-page":"2409","volume":"15","author":"AJ Wood","year":"1983","unstructured":"Wood AJ, Maurer G, Niederberger W, Beveridge T. Cyclosporine: pharmacokinetics metabolism and drug interactions. Transplant Proc. 1983;15:2409\u201312.","journal-title":"Transplant Proc."},{"key":"490_CR8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00007890-198712000-00019","volume":"44","author":"D Chabannes","year":"1987","unstructured":"Chabannes D, Moreau JF, Soulillou JP. Effect of cyclosporine, cyclosporine metabolite 17, and other cyclosporine-related compounds on T lymphocyte clones derived from rejected human kidney grafts. I. Inhibition of proliferation. Transplantation. 1987;44:813\u20137.","journal-title":"Transplantation."},{"key":"490_CR9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0009-9236(95)90032-2","volume":"57","author":"MP Duchame","year":"1995","unstructured":"Duchame MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995;57:485\u201391.","journal-title":"Clin Pharmacol Ther"},{"key":"490_CR10","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/archinte.1992.00400200011003","volume":"152","author":"M Epstein","year":"1992","unstructured":"Epstein M. Calcium antagonists and renal protection. Current status and future perspectives. Arch Intern Med. 1992;152:1573\u201384.","journal-title":"Arch Intern Med"},{"key":"490_CR11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2125.1990.tb03677.x","volume":"29","author":"A Lindholm","year":"1990","unstructured":"Lindholm A, Henricsson S, Dahlqvist R. The effect of food and bile acid administration on the relative bioavailability of cyclosporin. Br J Clin Pharmacol. 1990;29:541\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"490_CR12","first-page":"591","volume":"25","author":"MR First","year":"1993","unstructured":"First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW. Safety and efficacy of long-term cyclosporine-ketoconazole administration and preliminary results of a randomized trial. Transplant Proc. 1993;25:591\u20134.","journal-title":"Transplant Proc."},{"key":"490_CR13","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1046\/j.1523-1755.2002.00386.x","volume":"61","author":"SP McDonald","year":"2002","unstructured":"McDonald SP, Russ GR. Associations between cyclosporine-sparing agents and outcomes in kidney transplant recipients. Kidney Int. 2002;61:2259\u201365.","journal-title":"Kidney Int"},{"key":"490_CR14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1399-0012.1994.tb00959.x","volume":"8","author":"SD Ladefoged","year":"1994","unstructured":"Ladefoged SD, Andersen CB. Calcium channel blockers in kidney transplantation. Clin Transplant. 1994;8:128\u201333.","journal-title":"Clin Transplant"},{"key":"490_CR15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1445-5994.1996.tb00623.x","volume":"26","author":"TE Jones","year":"1996","unstructured":"Jones TE. Survey of cyclosporin-sparing agent use in Australasian transplant centers. Aust N Z J Med. 1996;26:772\u20136.","journal-title":"Aust N Z J Med."},{"key":"490_CR16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/j.1875-9114.1994.tb02839.x","volume":"14","author":"CL Smith","year":"1994","unstructured":"Smith CL, Hampton EM, Pederson JA, Pennington LR, Bourne DWA. Clinical and medicoeconomic impact of cyclosporine\u2013diltiazem interaction in renal transplant recipients. Pharmacotherapy. 1994;14:471\u201381.","journal-title":"Pharmacotherapy."},{"key":"490_CR17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s002280050644","volume":"55","author":"A Asberg","year":"1999","unstructured":"Asberg A, Christensen H, Hartmann A, Carlson E, Molden E, Berg KJ. Pharmacokinetic interactions between microemulsion formulated cyclosporin A and diltiazem in renal transplant recipients. Eur J Clin Pharmacol. 1999;55:383\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"490_CR18","first-page":"3955","volume":"21","author":"J McCauley","year":"1989","unstructured":"McCauley J, Ptachcinski RJ, Shapiro R. The cyclosporin-sparing effects of diltiazem in renal transplantation. Transplant Proc. 1989;21:3955\u20137.","journal-title":"Transplant Proc."},{"key":"490_CR19","first-page":"2127","volume":"22","author":"JJ Kelly","year":"1990","unstructured":"Kelly JJ, Walker RG, d\u2019Apice AJF, Kincaid-Smith P. A prospective study of the effect of diltiazem in renal allograft recipients receiving cyclosporin A: preliminary results. Transplant Proc. 1990;22:2127\u20138.","journal-title":"Transplant Proc."},{"key":"490_CR20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00007890-199302000-00014","volume":"55","author":"A Chrysostomou","year":"1993","unstructured":"Chrysostomou A, Walker RG, Russ GR, d\u2019Apice AJF, Kincaid-Smith P, Mathew TH. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation. 1993;55:300\u20134.","journal-title":"Transplantation"},{"key":"490_CR21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/ndt\/9.5.543","volume":"9","author":"SD Ladefoged","year":"1994","unstructured":"Ladefoged SD, Pedersen E, Hammer M, Rasmussen KC, Hansen FM, Andersen CB. Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 1994;9:543\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"490_CR22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1046\/j.1365-2125.1997.t01-1-00616.x","volume":"44","author":"TE Jones","year":"1997","unstructured":"Jones TE, Morris RG, Mathew TH. Diltiazem\u2013cyclosporin pharmacokinetic interaction\u2014dose\u2013response relationship. Br J Clin Pharmacol. 1997;44:499\u2013504.","journal-title":"Br J Clin Pharmacol"},{"key":"490_CR23","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2165\/00003495-200161130-00006","volume":"61","author":"CJ Dunn","year":"2001","unstructured":"Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsions-based formulation (Neoral\u00ae) in organ transplantation. Drugs. 2001;61:1957\u20132016.","journal-title":"Drugs."},{"key":"490_CR24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5694\/j.1326-5377.1992.tb137177.x","volume":"157","author":"DM Leibbrandt","year":"1992","unstructured":"Leibbrandt DM, Day RO. Cyclosporin and calcium channel blockers: an exploitable drug interaction? Med J Aust. 1992;157:296\u20137.","journal-title":"Med J Aust"},{"key":"490_CR25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2165\/00003088-199732050-00002","volume":"32","author":"TE Jones","year":"1997","unstructured":"Jones TE. The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations. Clin Pharmacokinet. 1997;32:357\u201367.","journal-title":"Clin Pharmacokinet."},{"key":"490_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000055614","volume":"32","author":"XY Zhang","year":"2000","unstructured":"Zhang XY, Hiraki S, Kadoi C, Hayasaka S. Effects of nilvadipine, nicardipine and verapamil on acute rise of aqueous flare induced by iris photocoagulation or intravenous lipopolysaccharides in pigmented rabbits. Ophthalmic Res. 2000;32:205\u20139.","journal-title":"Ophthalmic Res"},{"key":"490_CR27","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10384-010-0862-5","volume":"54","author":"S Ishida","year":"2010","unstructured":"Ishida S, Koto T, Nagai N, Oike Y. Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis. Jpn J Ophthalmol. 2010;54:594\u2013601.","journal-title":"Jpn J Ophthalmol"},{"key":"490_CR28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509\u201316.","journal-title":"Am J Ophthalmol"},{"key":"490_CR29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","volume":"4","author":"RB Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;4:467\u201371.","journal-title":"Ophthalmology"},{"key":"490_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-77174-3_1","volume-title":"Uveitis scoring system","author":"D Ben Ezra","year":"1991","unstructured":"Ben Ezra D, Forrester JV, Nussenblatt RB, Tabbara K, Timonen P. Uveitis scoring system. Berlin: Spriger Verlag; 1991. p. 1\u201313."},{"key":"490_CR31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492\u2013513.","journal-title":"Am J Ophthalmol"},{"key":"490_CR32","first-page":"1195","volume":"16","author":"BD Kahan","year":"1984","unstructured":"Kahan BD, Wideman CA, Reid M, Gibbons S, Jarowenko M, Flechner S, et al. The value of serial serum trough cyclosporine levels in human renal transplantation. Transplant Proc. 1984;16:1195\u20139.","journal-title":"Transplant Proc"},{"key":"490_CR33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00007890-198602000-00030","volume":"41","author":"ME Rogerson","year":"1986","unstructured":"Rogerson ME, Marsden JT, Reid KE, Bewick M, Holt DW. Cyclosporine blood concentrations in the management of renal transplant recipients. Transplantation. 1986;41:276\u20138.","journal-title":"Transplantation."},{"key":"490_CR34","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1097\/01.ASN.0000034945.61533.26","volume":"13","author":"CI Bagnis","year":"2002","unstructured":"Bagnis CI, du Montcel ST, Beaufils H, Jouanneau C, Jaudon MC, Maksud P, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002;13:2962\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"490_CR35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/0301-4738.58472","volume":"58","author":"D Mathews","year":"2010","unstructured":"Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol. 2010;58:55\u20138.","journal-title":"Indian J Ophthalmol"},{"key":"490_CR36","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(86)91699-5","volume":"1","author":"JM Gri\u00f1o","year":"1986","unstructured":"Gri\u00f1o JM, Sabate I, Castelao AM, Alsina J. Influence of diltiazem on cyclosporin clearance. Lancet. 1986;1:1387.","journal-title":"Lancet"},{"key":"490_CR37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1674-8301(10)60044-9","volume":"24","author":"W Xue","year":"2010","unstructured":"Xue W, Song Y, Tian P, Ding X, Pan X, Yan H, et al. The effects of diltiazem in renal transplantation patients treated with cyclosporine-A. J Biomed Res. 2010;24:317\u201323.","journal-title":"J Biomed Res."},{"key":"490_CR38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/clpt.1989.202","volume":"46","author":"LF Roy","year":"1989","unstructured":"Roy LF, East DS, Browning FM, Shaw D, Ogilvie RI, Cardella C, et al. Short-term effects of calcium antagonists on hemodynamics and cyclosporine pharmacokinetics in heart-transplant and kidney-transplant patients. Clin Pharmacol Ther. 1989;46:657\u201367.","journal-title":"Clin Pharmacol Ther"},{"key":"490_CR39","first-page":"561","volume":"2","author":"K Wagner","year":"1988","unstructured":"Wagner K, Henkel M, Heinemeyer G, Neumayer HH. Interaction of calcium blockers and cyclosporine. Transplant Proc. 1988;2:561\u20138.","journal-title":"Transplant Proc."},{"key":"490_CR40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0002-9343(91)90587-N","volume":"90","author":"RC Bourge","year":"1991","unstructured":"Bourge RC, Kirklin JK, Naftel DC, Figg WD, White-Williams C, Ketchum C. Diltiazem-cyclosporine interaction in cardiac transplant recipients: impact on cyclosporine dose and medication costs. Am J Med. 1991;90:402\u20134.","journal-title":"Am J Med"},{"key":"490_CR41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2125.1996.34412.x","volume":"41","author":"JS Bleck","year":"1996","unstructured":"Bleck JS, Thiesemann C, Kliem V, Christians U, Hecker H, Repp H, et al. Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients. Br J Clin Pharmacol. 1996;41:551\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"490_CR42","first-page":"595","volume":"60","author":"CE Vari","year":"2012","unstructured":"Vari CE, Vescan AT, Imre S, Muntean DL. Therapeutic drug monitoring of cyclosporine in transplanted patients. Possibilities, controversy, causes for failure. Farmacia. 2012;60:595\u2013601.","journal-title":"Farmacia"},{"key":"490_CR43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/lt.500010609","volume":"1","author":"M Al Edreesi","year":"1995","unstructured":"Al Edreesi M, Caill\u00e9 G, Dupuis C, Th\u00e9oret Y, Paradis K. Safety, tolerability, and pharmacokinetic actions of diltiazem in pediatric liver transplant recipients on cyclosporine. Liver Transpl Surg. 1995;1:383\u20138.","journal-title":"Liver Transpl Surg."},{"key":"490_CR44","first-page":"2383","volume":"23","author":"A Alcaraz","year":"1991","unstructured":"Alcaraz A, Oppenheimer F, Talbot-W R, Fernandez L, Manfialich M, Garcia PE, et al. Effect of diltiazem in the prevention of acute tubular necrosis, acute rejection, and cyclosporine levels. Transplant Proc. 1991;23:2383\u20134.","journal-title":"Transplant Proc."},{"key":"490_CR45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00007890-199108000-00018","volume":"52","author":"U Kunzendorf","year":"1991","unstructured":"Kunzendorf U, Walz G, Brockmoeller J, Neumayer HH, Jochimsen F, Roots I, et al. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation. 1991;52:280\u20134.","journal-title":"Transplantation"},{"key":"490_CR46","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<900::AID-IJC32>3.0.CO;2-8","volume":"71","author":"G Toffoli","year":"1997","unstructured":"Toffoli G, Corona G, Sorio R, Bertola A, Boiocchi M. Reversal activity of cyclosporin A and its metabolites M1, M17 and M21 in multidrug-resistant cells. Int J Cancer. 1997;71:900\u20136.","journal-title":"Int J Cancer"},{"key":"490_CR47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00228-008-0577-4","volume":"65","author":"Y Wang","year":"2009","unstructured":"Wang Y, Wang C, Li J, Wang X, Zhu G, Chen X, et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur J Clin Pharmacol. 2009;65:239\u201347.","journal-title":"Eur J Clin Pharmacol"},{"key":"490_CR48","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/0309-1651(91)90096-2","volume":"15","author":"PD Wilson","year":"1991","unstructured":"Wilson PD, Hartz PA. Mechanisms of cyclosporine-A toxicity in defined cultures of renal tubule epithelia: a role for cysteine proteases. Cell Biol Int Rep. 1991;15:1243\u201358.","journal-title":"Cell Biol Int Rep"},{"key":"490_CR49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.brainres.2005.11.072","volume":"1071","author":"H Yamada","year":"2006","unstructured":"Yamada H, Chen YN, Aihara M, Araie M. Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia. Brain Res. 2006;1071:75\u201380.","journal-title":"Brain Res"},{"key":"490_CR50","first-page":"1399","volume":"22","author":"J Garc\u00eda-Campos","year":"2007","unstructured":"Garc\u00eda-Campos J, Villena A, D\u00edaz F, Vidal L, Moreno M, P\u00e9rez de Vargas I. Morphological and functional changes in experimental ocular hypertension and role of neuroprotective drugs. Histol Histopathol. 2007;22:1399\u2013411.","journal-title":"Histol Histopathol"},{"key":"490_CR51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.preteyeres.2010.09.002","volume":"30","author":"M Araie","year":"2011","unstructured":"Araie M, Yamaya C. Use of calcium channel blockers for glaucoma. Prog Ret Eye Res. 2011;30:54\u201371.","journal-title":"Prog Ret Eye Res."},{"key":"490_CR52","first-page":"121","volume":"43","author":"M Nakazawa","year":"2011","unstructured":"Nakazawa M. Effects of calcium ion, calpains, and calcium channel blockers on retinitis pigmentosa. J Ophthalmol. 2011;43:121\u20137.","journal-title":"J Ophthalmol."}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-016-0490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-016-0490-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-016-0490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:39:25Z","timestamp":1749818365000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-016-0490-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,10]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1007\/s10384-016-0490-9","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,10]]}}}